Cellectar Biosciences, Inc. (CLRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLRB Stock Price Chart Interactive Chart >
CLRB Price/Volume Stats
| Current price | $0.44 | 52-week high | $1.84 |
| Prev. close | $0.40 | 52-week low | $0.34 |
| Day low | $0.39 | Volume | 85,400 |
| Day high | $0.48 | Avg. volume | 191,701 |
| 50-day MA | $0.55 | Dividend yield | N/A |
| 200-day MA | $0.70 | Market Cap | 26.88M |
Cellectar Biosciences, Inc. (CLRB) Company Bio
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is based in Madison, Wisconsin.
Latest CLRB News From Around the Web
Below are the latest news stories about Cellectar Biosciences Inc that investors may wish to consider to help them evaluate CLRB as an investment opportunity.
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year. |
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and ZymeworksRentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article. |
Ride on Rising P/E Investing With These 5 Top-Ranked StocksWant to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios. |
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect ConferenceFLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced Jim Caruso, president and CEO and Jarrod Longcor, CBO, will participate in a fireside chat at the H.C. Wainwright Bioconnect conference taking place virtually January 10-13, 2022. The fireside chat will be available on demand begin |
Cellectar Biosciences’ (CLRB) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated their buy rating on shares of Cellectar Biosciences (NASDAQ:CLRB) in a research report sent to investors on Monday, AnalystRatings.com reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. Separately, Zacks Investment Research cut Cellectar Biosciences from a buy rating to a hold rating in a research note on […] |
CLRB Price Returns
| 1-mo | -14.61% |
| 3-mo | -8.31% |
| 6-mo | -36.43% |
| 1-year | -73.17% |
| 3-year | -81.36% |
| 5-year | -97.35% |
| YTD | -33.73% |
| 2021 | -68.08% |
| 2020 | -7.56% |
| 2019 | 45.16% |
| 2018 | -88.69% |
| 2017 | 12.30% |
Loading social stream, please wait...